H.C. Wainwright lowered the firm’s price target on Ocugen (OCGN) to $7 from $8 and keeps a Buy rating on the shares following the Q1 report. The firm says the company is targeting OCU400 approval in 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN: